In December 2015, Celgene exercised the ex vivo RORγ agonist license. Under the terms of the ex vivo license agreement, Lycera received a $17.5 million upfront cash payment and has the potential to receive an additional near-term milestone payment of $5 million.
In 2017, Lycera and Celgene also entered into a license agreement for Lycera’s RORγ Antagonist Program.
Lycera Corp. was founded by Gary Glick, PhD, Werner E. Bachman Professor of Chemistry at the University of Michigan based on technology developed in Dr. Glick’s laboratory and in-licensed from the University of Michigan. The program focuses on ATPase modulators, which Lycera advanced to a clinical stage.